SS Innovations' Robotic System Expands to Americas with First Cardiac Surgery in Ecuador

SS Innovations International, an emerging player in the surgical robotics market, has marked a significant milestone with the first robotic cardiac surgery in the Americas using its SSi Mantra 3 system. The procedure, performed at Interhospital in Guayaquil, Ecuador, represents a major step in the company's global expansion strategy and its entry into the competitive cardiovascular surgery market.

Groundbreaking Cardiac Procedure in South America

The robotic atrial septal defect closure, which repaired a hole between the upper two chambers of the patient's heart, was successfully conducted at Interhospital, the first South American hospital to install the SSi Mantra robot. Dr. Juan Zuniga, a cardiothoracic surgeon at Interhospital who performed the procedure, reported positive outcomes, stating, "The experience was good, this equipment was very easy to handle and manipulate, and the results were effective. The patient is recovering very well."

This cardiac surgery marks an expansion of the system's capabilities at Interhospital, where it has already been used for other complex surgeries since its installation. The successful operation not only demonstrates the versatility of the SSi Mantra 3 system but also positions SS Innovations as a contender in the robotic cardiac surgery arena.

Global Expansion and Market Position

SS Innovations, which recently began trading on the Nasdaq market in April, is pursuing an aggressive global expansion strategy. The company reports that 80 SSi Mantra systems have been installed in 75 hospitals across India and other countries. In May, SS Innovations announced that more than 4,000 robotic surgeries had been performed using the SSi Mantra system without complications, injuries, or mortalities. This milestone encompassed over 100 types of procedures, including approximately 215 cardiac procedures, with six being telesurgeries.

The India-based company is positioning itself as a competitor to market leader Intuitive Surgical, emphasizing its technologically advanced system that aims to be both affordable and accessible to a larger segment of patients globally. This strategy appears to be gaining traction, as evidenced by the company's financial performance. SS Innovations reported a 41% year-over-year increase in first-quarter revenue to $5.1 million, with its quarterly net loss narrowing to $5.7 million from $9.8 million.

Regulatory Outlook and Future Plans

SS Innovations is actively pursuing regulatory approvals to expand its market reach. The company has announced plans to obtain CE marking in Europe later this year and is targeting FDA market clearance in the first half of 2026. A crucial step in this process is the anticipated submission of a de novo classification request for the SSi Mantra 3 system to the FDA in July, covering multiple surgical indications.

As SS Innovations continues to make strides in the surgical robotics field, its recent achievements and ambitious plans suggest that the competitive landscape in robotic-assisted surgery may be poised for significant changes in the coming years.